Elevance Health (NYSE:ELV) Price Target Raised to $360.00

Elevance Health (NYSE:ELV) had its price target increased by Evercore from $345.00 to $360.00 in a research report released on Thursday morning,MarketScreener reports.

A number of other equities research analysts have also recently issued reports on ELV. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Jefferies Financial Group decreased their target price on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. UBS Group set a $400.00 target price on Elevance Health in a report on Thursday, January 29th. JPMorgan Chase & Co. boosted their target price on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Robert W. Baird boosted their target price on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday. Eleven analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $380.42.

Elevance Health Trading Down 0.5%

Shares of Elevance Health stock opened at $344.64 on Thursday. Elevance Health has a 12-month low of $273.71 and a 12-month high of $427.54. The stock has a market cap of $74.84 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.84 and a beta of 0.49. The company has a quick ratio of 1.54, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The business’s 50 day moving average is $308.96 and its 200-day moving average is $331.44.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the business posted $11.97 EPS. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts predict that Elevance Health will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s payout ratio is presently 27.39%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after buying an additional 141,747 shares in the last quarter. Wellington Management Group LLP grew its holdings in Elevance Health by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock valued at $2,906,051,000 after buying an additional 1,668,679 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Elevance Health by 27.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after buying an additional 1,607,274 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Elevance Health by 10.0% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock valued at $1,764,231,000 after buying an additional 455,946 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its holdings in Elevance Health by 0.6% in the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after buying an additional 24,271 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an “outperform” rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird’s update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.